CoChat

Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

Crosignani, P.G., Luciano, A., Ray, A., Bergqvist, A. · 2006 · Human Reproduction

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

BACKGROUND: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. METHODS: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. RESULTS: DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P < or = 0.05) improved in both groups at 6 and 18 months. CONCLUSIONS: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

Overview

Integrity signals

Registry

Crossref · 10.1093/humrep/dei290

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 179

Metadata

Authors
Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A.
Affiliations
  • University of Milan (IT)
  • University of Connecticut (US)
  • Pfizer (United States) (US)
  • Danderyds sjukhus (SE)
Corresponding author
Crosignani, P.G.
Venue
Human Reproduction
Published
2005-09-21
Volume
21
Issue
1
Pages
248-256
ISSN
  • 0268-1161 (ISSN-L)
  • 1460-2350
OpenAlex
W2169590550
Cited by
179
References
42
Citations by year
2026: 8 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 14 · 2017: 10 · 2016: 6 · 2015: 11 · 2014: 7 · 2013: 10 · 2012: 10
FWCI
5.96
Type
journal article
Language
en
Open access
closed
Locations
  • Human Reproduction (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
Keywords
endometriosis, endometriosis-associated pain, depot medroxyprogesterone acetate, leuprolide, subcutaneous injection, dysmenorrhea, dyspareunia, pelvic pain, bone mineral density, bone loss, labor productivity, GnRH agonist, GnRH antagonist
MeSH terms
Administration, Cutaneous, Adult, Contraceptive Agents, Female, Endometriosis, Female, Fertility Agents, Female, Hip, Humans, Lumbar Vertebrae, Quality of Life, Radiography, Uterine Diseases, Bone Density, Leuprolide, Treatment Outcome, Medroxyprogesterone Acetate, Pelvic Pain, Antineoplastic Agents, Hormonal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.